<DOC>
	<DOC>NCT00144495</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.</brief_summary>
	<brief_title>A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Cancer patients a history of myocardial, cerebral or pulmonary infarction severe hypertension beyond control by drugs</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>